SLDB

Solid Biosciences Inc.

There isn't enough reported data to score SLDB yet.

SLDB Fundamentals

MetricStatus
Unavailable
Under pressure
Unavailable
Unavailable

SLDB's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.

SLDB PE Valuation

SLDB has no meaningful PE right now: it lost money over the past year.

SLDB Forward outlook

There aren't enough analyst estimates for SLDB to show an outlook.

SLDB Risk to reward

ScenarioChangePrice
UpsideUnknownโ€”
DownsideUnknownโ€”

Calculated from the latest close: $7.00 on Nov 12.

There is not enough scenario data to assess SLDB's risk to reward.

SLDB Earnings Per Share

Q4 2023: $-4.83Q1 2024: $-3.93Q2 2024: $-3.29Q3 2024: $-3.03Q4 2024: $-3.06Q1 2025: $-3.01Q2 2025: $-2.82Q3 2025: $-2.51Q4 2025: $-2.16Q1 2026: $-2.09Q2 2026: $-2.05Q3 2026: $-1.93
Q4 2023: $-4.83Q1 2024: $-3.93Q2 2024: $-3.29Q3 2024: $-3.03Q4 2024: $-3.06Q1 2025: $-3.01Q2 2025: $-2.82Q3 2025: $-2.51Q4 2025: $-2.16Q1 2026: $-2.09Q2 2026: $-2.05Q3 2026: $-1.93
QuarterTTM EPSYoY
Q3 2026-$1.93+$0.58
Q2 2026-$2.05+$0.77
Q1 2026-$2.09+$0.92
Q4 2025-$2.16+$0.90
Q3 2025-$2.51+$0.52
Q2 2025-$2.82+$0.47
Q1 2025-$3.01+$0.92
Q4 2024-$3.06+$1.77

SLDB is still losing money, but far less than before: $1.93 per share over the past year, against $44.25 at its worst in late 2019.

SLDB Quarterly Revenue

Q4 2023: --Q1 2024: --Q2 2024: --Q3 2024: --Q4 2024: --Q1 2025: --Q2 2025: --Q3 2025: --Q4 2025: --Q1 2026: --Q2 2026: --Q3 2026: --
Q4 2023: --Q1 2024: --Q2 2024: --Q3 2024: --Q4 2024: --Q1 2025: --Q2 2025: --Q3 2025: --Q4 2025: --Q1 2026: --Q2 2026: --Q3 2026: --

SLDB Free Cash Flow

Q4 2023: โˆ’$21MQ1 2024: โˆ’$25MQ2 2024: โˆ’$22MQ3 2024: โˆ’$24MQ4 2024: โˆ’$30MQ1 2025: โˆ’$32MQ2 2025: โˆ’$38MQ3 2025: โˆ’$34MQ4 2025: โˆ’$54MQ1 2026: โˆ’$47MQ2 2026: โˆ’$53MQ3 2026: โˆ’$46M
Q4 2023: โˆ’$21MQ1 2024: โˆ’$25MQ2 2024: โˆ’$22MQ3 2024: โˆ’$24MQ4 2024: โˆ’$30MQ1 2025: โˆ’$32MQ2 2025: โˆ’$38MQ3 2025: โˆ’$34MQ4 2025: โˆ’$54MQ1 2026: โˆ’$47MQ2 2026: โˆ’$53MQ3 2026: โˆ’$46M
QuarterFree cash flowYoY
Q3 2026-$46M-$12.5M
Q2 2026-$52.7M-$14.9M
Q1 2026-$47.4M-$15.4M
Q4 2025-$54.1M-$24.3M
Q3 2025-$33.6M-$9.8M
Q2 2025-$37.8M-$16M
Q1 2025-$32M-$6.6M
Q4 2024-$29.8M-$8.9M

SLDB has burned cash in almost every quarter: โˆ’$200M over the past year, against โˆ’$133M the year before.

SLDB Total Shares

Q1 2024: 38MQ2 2024: 41MQ3 2024: 41MQ1 2025: 66MQ2 2025: 94MQ3 2025: 94MQ4 2025: 88MQ1 2026: 110MQ2 2026: 144MQ3 2026: 151M
Q1 2024: 38MQ2 2024: 41MQ3 2024: 41MQ1 2025: 66MQ2 2025: 94MQ3 2025: 94MQ4 2025: 88MQ1 2026: 110MQ2 2026: 144MQ3 2026: 151M
PeriodChange %Net change
Quarterly+5.1%+7.3M shares
1 year+60%+56.6M shares
3 years+672%+131M shares
5 years+4591%+148M shares

SLDB has 151M diluted shares, up 60% from a year ago.

SLDB Net Leverage

SLDB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

SLDB Weekly Momentum

MetricValueStatus
RSI46.8Neutral
Stochastic23.8Neutral

SLDB's weekly RSI is 47 (neutral) and its Stochastic is 24 (neutral).

SLDB PE vs Healthcare Sector

SLDB has no meaningful PE right now: it lost money over the past year.

SLDB Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$6.537.2% above
20 week MA$8.1314% below
50 week MA$7.344.6% below
100 week MA$6.0017% above
200 week MA$6.1913% above

SLDB's trend is mixed: it's above three of its five weekly moving averages, and 13% above its 200-week average.

SLDB Yearly ROI

YearStart priceEnd priceROI
2020$64.2$102.5+60%
2021$102.5$28.7-72%
2022$28.7$5.64-80%
2023$5.64$6.14+8.9%
2024$6.14$4.24-31%
2025$4.24$5.84+38%
2026 YTD$5.84$7.00+20%

SLDB has finished lower in three of the last six years. It's up 20% so far in 2026.

Give your agent the market.

Get API key